NCS-382

	WikiDoc Resources for NCS-382
Articles
Most recent articles on NCS-382 Most cited articles on NCS-382 Review articles on NCS-382 Articles on NCS-382 in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on NCS-382 Images of NCS-382 Photos of NCS-382 Podcasts & MP3s on NCS-382 Videos on NCS-382
Evidence Based Medicine
Cochrane Collaboration on NCS-382 Bandolier on NCS-382 TRIP on NCS-382
Clinical Trials
Ongoing Trials on NCS-382 at Clinical Trials.gov Trial results on NCS-382 Clinical Trials on NCS-382 at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on NCS-382 NICE Guidance on NCS-382 NHS PRODIGY Guidance FDA on NCS-382 CDC on NCS-382
Books
Books on NCS-382
News
NCS-382 in the news Be alerted to news on NCS-382 News trends on NCS-382
Commentary
Blogs on NCS-382
Definitions
Definitions of NCS-382
Patient Resources / Community
Patient resources on NCS-382 Discussion groups on NCS-382 Patient Handouts on NCS-382 Directions to Hospitals Treating NCS-382 Risk calculators and risk factors for NCS-382
Healthcare Provider Resources
Symptoms of NCS-382 Causes & Risk Factors for NCS-382 Diagnostic studies for NCS-382 Treatment of NCS-382
Continuing Medical Education (CME)
CME Programs on NCS-382
International
NCS-382 en Espanol NCS-382 en Francais
Business
NCS-382 in the Marketplace Patents on NCS-382
Experimental / Informatics
List of terms related to NCS-382

NCS-382 is a moderately selective antagonist for the GHB receptor.^[1] It blocks the effects of GHB in animals and has both anti-sedative and anticonvulsant effects.^[2]^[3]^[4] It has been proposed as a treatment for GHB overdose in humans, as well as for the endogenous metabolic disorder succinic semialdehyde dehydrogenase deficiency, but has never been developed for clinical use.^[5]

References

↑ Castelli MP, Pibiri F, Carboni G, Piras AP. A review of pharmacology of NCS-382, a putative antagonist of gamma-hydroxybutyric acid (GHB) receptor. CNS Drug Reviews. 2004 Fall;10(3):243-60. PMID 15492774
↑ Maitre M, Hechler V, Vayer P, Gobaille S, Cash CD, Schmitt M, Bourguignon JJ. A specific gamma-hydroxybutyrate receptor ligand possesses both antagonistic and anticonvulsant properties. Journal of Pharmacology and Experimental Therapeutics. 1990 Nov;255(2):657-63. PMID 2173754
↑ Schmidt C, Gobaille S, Hechler V, Schmitt M, Bourguignon JJ, Maitre M. Anti-sedative and anti-cataleptic properties of NCS-382, a gamma-hydroxybutyrate receptor antagonist. European Journal of Pharmacology. 1991 Oct 22;203(3):393-7. PMID 1773824
↑ Colombo G, Agabio R, Bourguignon J, Fadda F, Lobina C, Maitre M, Reali R, Schmitt M, Gessa GL. Blockade of the discriminative stimulus effects of gamma-hydroxybutyric acid (GHB) by the GHB receptor antagonist NCS-382. Physiology and Behaviour. 1995 Sep;58(3):587-90. PMID 8587968
↑ Gupta M, Greven R, Jansen EE, Jakobs C, Hogema BM, Froestl W, Snead OC, Bartels H, Grompe M, Gibson KM. Therapeutic intervention in mice deficient for succinate semialdehyde dehydrogenase (gamma-hydroxybutyric aciduria). Journal of Pharmacology and Experimental Therapeutics. 2002 Jul;302(1):180-7. PMID 12065715